Fast, accurate, and easy disease detection that has the potential to expand care, improve outcomes, and lower healthcare costs worldwide.
Press Release - PhageTech Clinical Trial Start
IRVINE, Calif., March 19, 2021 – PhageTech, Inc. (PhageTech), a privately held company pioneering a novel point-of-care diagnostic system, today announced the first patient enrollment in its trial of the Virus BioResistor (VBR) for bladder cancer screening. The trial is being conducted at two Orange County, CA area hospitals specializing in bladder cancer treatment, Providence Saint John’s Cancer Institute and Hoag Hospital under principal investigators Jennifer Linehan, M.D. and Jeffrey Yoshida, M.D. This trial will confirm the ability of the PhageTech VBR to detect multiple bladder cancer biomarkers non-invasively in a simple urine sample.